William Hall

15PUBLICATIONS
142CO-AUTHORS
Molecular targetsPredictive and prognostic markersRadiation therapyCancer therapy (excl. chemotherapy and radiation therapy)Medical robotics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Oct 24, 2025
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Mandana Kamgar, G Aaron Hobbes, Raven Davidson

|Oct 02, 2025
Radiogenomic Profiling of Prostate Tumors prior to External Beam Radiotherapy Converges on a Transcriptomic Signature of TGF-β Activity Driving Tumor Recurrence.

Anson T Ku, Uma Shankavaram, Shana Y Trostel

|Mar 03, 2025
A Polygenic Risk Score for Late Bladder Toxicity Following Radiotherapy for Non-Metastatic Prostate Cancer.

Manzur Farazi, Xin Yang, Carson J Gehl

|May 17, 2024
Long-Term Analysis of NRG Oncology RTOG 0415: A Randomized Phase III Noninferiority Study Comparing Two Fractionation Schedules in Patients With Low-Risk Prostate Cancer.

W Robert Lee, James J Dignam, Mahul B Amin

|Jan 18, 2024
Re-Examining Trials of Radiotherapy Omission: When Less Is Not Always More.

Nina N Sanford, William A Hall, Christopher M Booth

|Dec 23, 2023
Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

Saryleine de Ortiz de Choudens, Alexis Visotcky, Anjishnu Banerjee

Pageof 3

Frequent Collaborators

3 joint publications

Theodore S Hong

3 joint publications

Howard M Sandler

2 joint publications

Daniel E Spratt

2 joint publications

X Allen Li